In patients with type 2 diabetes, the adequate control of the different cardiovascular risk factors is essential, which entails that in addition to glycemic control, control of blood pressure, lipid and weight is carried out.And just at this point it is where experts are raising the use of antidiabetic drugs, not so much for their power over glycemic control, but for their demonstrated action of cardiovascular protection.
The health newspaper has that the latest studies in diabetes aimed at checking cardiovascular safety of certain drugs have shown that they also have an additional cardiovascular protection effect in patients with type 2 diabetes mellitus and cardiovascular disease Previous or high cardiovascular risk.
The advances in the treatments of people with diabetes and their application in clinical practice will be analyzed and released on April 6 and 7 in Pamplona in the V Days in Diabetes of the Spanish Society of General and Family Physicians (Semg) by the hand of renowned experts, among which are Dr. Francisco Javier Escalada San Martín, specialist in endocrinology and nutrition.
The climbing doctor explained that, after the aforementioned findings, the clinical guides of diabetes treatment have begun to incorporate the recommendation of use of these drugs in patients with patients with type 2 diabetes and cardiovascular disease present, that is, whatWe know as secondary prevention.
In our country, the guides in this regard are updated by the Spanish Diabetes Society (SED) and the Spanish Society of Endocrinology and Nutrition (SEEN), which also collect these recommendations and that will be published soon.
As for the improvements that are expected in the coming years for the treatment of diabetes, Escalada points out that new molecules are still investigated within the already known families, but drugs are also being tested that combine different molecules.Likewise, he points out that he continues to investigate in the development of insulins better than the current ones.
In addition to the latest studies and advances in diabetes, other matters of interest for family doctors who will be addressed in Pamplona during the V Conference in SEMG diabetes will be to discuss how to combine humanization and chronicity in the follow -up of diabetes, orHow to achieve polypharmacy conciliation and control objectives.
